These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 21455568)

  • 21. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases.
    Bonavida B; Baritaki S; Huerta-Yepez S; Vega MI; Chatterjee D; Yeung K
    Nitric Oxide; 2008 Sep; 19(2):152-7. PubMed ID: 18477483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics.
    Bonavida B; Garban H
    Redox Biol; 2015 Dec; 6():486-494. PubMed ID: 26432660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation.
    Bortul R; Tazzari PL; Cappellini A; Tabellini G; Billi AM; Bareggi R; Manzoli L; Cocco L; Martelli AM
    Leukemia; 2003 Feb; 17(2):379-89. PubMed ID: 12592338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
    Yang J; Li G; Zhang K
    Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
    Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy.
    Rapozzi V; Della Pietra E; Bonavida B
    Redox Biol; 2015 Dec; 6():311-317. PubMed ID: 26319434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B; Vega MI
    Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
    Vega MI; Martinez-Paniagua M; Jazirehi AR; Huerta-Yepez S; Umezawa K; Martinez-Maza O; Bonavida B
    Leuk Lymphoma; 2008 Oct; 49(10):1982-94. PubMed ID: 18949621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What signals are generated by anti-CD20 antibody therapy?
    Bonavida B
    Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
    Mitsiades CS; Mitsiades N; Poulaki V; Schlossman R; Akiyama M; Chauhan D; Hideshima T; Treon SP; Munshi NC; Richardson PG; Anderson KC
    Oncogene; 2002 Aug; 21(37):5673-83. PubMed ID: 12173037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
    Vega MI; Huerta-Yepaz S; Garban H; Jazirehi A; Emmanouilides C; Bonavida B
    Oncogene; 2004 Apr; 23(20):3530-40. PubMed ID: 15077178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S; Emmanouilides C; Bonavida B
    Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
    Bonavida B
    Oncogene; 2007 May; 26(25):3629-36. PubMed ID: 17530016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-κB signaling.
    Rasheduzzaman M; Jeong JK; Park SY
    Life Sci; 2018 Sep; 208():208-220. PubMed ID: 30031063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.
    Baritaki S; Chapman A; Yeung K; Spandidos DA; Palladino M; Bonavida B
    Oncogene; 2009 Oct; 28(40):3573-85. PubMed ID: 19633685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells.
    Dida F; Li Y; Iwao A; Deguchi T; Azuma E; Komada Y
    Exp Hematol; 2008 Oct; 36(10):1343-53. PubMed ID: 18599181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis.
    Kim HS; Chang I; Kim JY; Choi KH; Lee MS
    Cancer Res; 2005 Jul; 65(14):6111-9. PubMed ID: 16024612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
    Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
    Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.
    Whang YE; Yuan XJ; Liu Y; Majumder S; Lewis TD
    Vitam Horm; 2004; 67():409-26. PubMed ID: 15110188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.